Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
- PMID: 10634377
- DOI: 10.1210/jcem.85.1.6293
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
Abstract
In the last few years some studies assessed the effects of attenuation of hyperinsulinemia and insulin resistance, obtained by insulin sensitizing agents, in women with polycystic ovary syndrome (PCOS), suggesting potential scope for these drugs in treating the whole spectrum of reproductive, endocrine, and metabolic abnormalities found in such subjects. However, the results of these studies, mostly uncontrolled and short-term, are still inconclusive, and there is no long-term follow-up. In the present study, 23 PCOS subjects [mean (+/- SE) body mass index 30.0+/-1.1 kg/m2] were randomly assigned to double-blind treatment with metformin (500 mg tid) or placebo for 6 months, while maintaining their usual eating habits. Before and after treatment, menstrual history, endocrine and metabolic profiles, serum 17-hydroxyprogesterone response to GnRH-agonist testing, and insulin sensitivity measured by the glucose clamp technique were assessed. Eighteen of these women, as well as 14 additional PCOS patients, were subsequently given metformin in an open trial for 11.0+/-1.3 months (range 4-26), to assess long-term effects of treatment and baseline predictors of metformin efficacy on reproductive abnormalities. After metformin treatment, mean frequency of menstruation improved (P = 0.002), due to striking amelioration of menstrual abnormalities in about 50% of subjects. Women given metformin showed reduced plasma insulin (at fasting: P = 0.057; during the clamp studies: P<0.01) and increased insulin sensitivity (P<0.05). Concurrently, ovarian hyperandrogenism was attenuated, as indicated by significant reductions in serum free testosterone (P<0.05) and in the 17-hydroxyprogesterone response to GnRH-agonist testing (P<0.05). No changes were found in the placebo group. Only comparable minor changes in body mass index were found both in the metformin group and in the placebo group. In the open, long-term trial 17 women (54.8%) showed striking improvements of their menstrual abnormalities and were considered as responders. Logistic regression analysis of baseline characteristics in responders and nonresponders showed that plasma insulin, serum androstenedione, and menstrual history were independent predictors of the treatment's clinical efficacy. In 10 subjects whose menses proved regular after treatment, the great majority of cycles became ovulatory (32 out of 39 assessed, 79%). In conclusion, in women with PCOS metformin treatment reduced hyperinsulinemia and hyperandrogenemia, independently of changes in body weight. In a large number of subjects these changes were associated with striking, sustained improvements in menstrual abnormalities and resumption of ovulation. Higher plasma insulin, lower serum androstenedione, and less severe menstrual abnormalities are baseline predictors of clinical response to metformin.
Comment in
-
Metformin and the polycystic ovary syndrome.J Clin Endocrinol Metab. 2001 Mar;86(3):1430. doi: 10.1210/jcem.86.3.7352-9. J Clin Endocrinol Metab. 2001. PMID: 11238551 No abstract available.
Similar articles
-
The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2011 May;96(5):E821-4. doi: 10.1210/jc.2010-1725. Epub 2011 Feb 9. J Clin Endocrinol Metab. 2011. PMID: 21307134
-
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.J Clin Endocrinol Metab. 2007 Nov;92(11):4208-17. doi: 10.1210/jc.2007-0870. Epub 2007 Sep 4. J Clin Endocrinol Metab. 2007. PMID: 17785360
-
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74. doi: 10.1210/jcem.85.8.6738. J Clin Endocrinol Metab. 2000. PMID: 10946879 Clinical Trial.
-
Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.Hum Reprod Update. 2015 Sep-Oct;21(5):560-74. doi: 10.1093/humupd/dmv025. Epub 2015 Jun 9. Hum Reprod Update. 2015. PMID: 26060208 Review.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.Endocr Pract. 2015 Dec;21(12):1415-26. doi: 10.4158/EP15748.DSCPT2. Endocr Pract. 2015. PMID: 26642102 Review.
Cited by
-
Effects of combined metformin and cabergoline versus metformin alone on ovarian and hormonal activities in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial.J Med Life. 2023 Nov;16(11):1615-1621. doi: 10.25122/jml-2023-0317. J Med Life. 2023. PMID: 38406771 Free PMC article. Clinical Trial.
-
A novel action of insulin sensitizing drug as a potential promotor of preovulatory follicles, ovulation rate and prolificacy in sheep.Vet Res Commun. 2024 Apr;48(2):849-863. doi: 10.1007/s11259-023-10259-y. Epub 2023 Nov 14. Vet Res Commun. 2024. PMID: 37957451
-
Role of Metformin in Polycystic Ovary Syndrome (PCOS)-Related Infertility.Cureus. 2023 Aug 31;15(8):e44493. doi: 10.7759/cureus.44493. eCollection 2023 Aug. Cureus. 2023. PMID: 37791160 Free PMC article. Review.
-
Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question.Pharmaceuticals (Basel). 2023 Sep 18;16(9):1318. doi: 10.3390/ph16091318. Pharmaceuticals (Basel). 2023. PMID: 37765126 Free PMC article. Review.
-
Hypothalamic-Pituitary-Gonadal Axis Disorders Impacting Fertility in Both Sexes and the Potential of Kisspeptin-Based Therapies to Treat Them.Handb Exp Pharmacol. 2023;282:259-288. doi: 10.1007/164_2023_666. Handb Exp Pharmacol. 2023. PMID: 37439848
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical